3SBio In-licenses Leukemia Antibody from DiNonA of Korea

3SBio Inc. in-licensed China rights to a clinical-stage treatment for acute leukemia from DiNonA Inc., a Korean biopharma. Leukotuximab is an anti JL-1 antibody. 3SBio will make upfront and milestone payments, plus pay royalties on revenues. Specific details were not disclosed. In 2013, 3SBio was taken private by the company’s Chairman/CEO and a CITIC Private Equity company for $394 million. More details.... Share this with colleagues: // //